DEPLOYDatabase

Company

Stereotaxis

Stereotaxis is an American medical device company based in St.

Track Stereotaxis
Founded
1990
HQ
St. Louis, MO, USA
Status
public (NYSE American: STXS)

The verified answer

As of Aug 2026, DEPLOY verifies Stereotaxis: 1 model, 1 active incident. 3 sources back the record.

Regulatory status1 FDA 510(k) clearance

Stereotaxis holds 1 FDA 510(k) clearance, per the DEPLOY registry.

See all 1 filings
PublicNYSE AMERICAN: STXS

CategorySurgical robots

Models

1

Overview

Stereotaxis is an American medical device company based in St. Louis, Missouri, developing magnetic navigation technology for robotic cardiology procedures. Its Genesis RMN system uses robotically controlled magnets to guide flexible catheters with magnetic tips during cardiac ablation procedures, and received FDA clearance and NMPA approval in China.

Verified record

Verified deployments
None on file
Active incidents
1 incident on file

Key facts

Product

Genesis RMN / GenesisX Robotic Magnetic Navigation

Gating events

GenesisX CE Aug 2024 + FDA 510(k) Nov 10 2025; MAGiC FDA Jan 6 2026.

Stock listing

NYSE American: STXS

Installed base

>100 RMN systems installed

CEO

David Fischel

Regulatory

FDA cleared, NMPA cleared (China)

Listed on

NYSE: STXS

Data & sources

Press releases

3

3 sources backing this record.View all →

Models (1)

View all models →

Current platform

Genesis RMN / GenesisX

Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.

surgicalView model →

Stereotaxis on the deployment map

View the global map

Stereotaxis has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

No verified deployments for Stereotaxis on the DEPLOY record yet. Track Stereotaxis to know the moment the first one is verified.

Free to use on your site, with a link back to DEPLOY.

Explainers

Plain-language answers to the questions people ask about Stereotaxis, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →

Current leadership (1)

Safety record

1 incident on record (1 minor). Most recent: Apr 2026.

minor
1

Most recent: Apr 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Stereotaxis (1)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Recent coverage

Stereotaxis in third-party press

Stereotaxis completes acquisition of Robocath

Jul 13, 2026

Stereotaxis Next-Gen Endovascular Surgical Robot Receives 510k Clearance from FDA

Jun 10, 2026

Stereotaxis Expands Endovascular Reach with 5M Robocath Acquisition

Apr 16, 2026

Peer companies